$120.69
1.33%
Nasdaq, Sep 02, 10:04 pm CET

Repligen Corporation Stock price

$120.69
+4.19 3.60% 1M
-34.69 22.33% 6M
-23.25 16.15% YTD
-30.24 20.04% 1Y
-89.65 42.62% 3Y
-35.37 22.66% 5Y
+85.77 245.62% 10Y
+116.81 3,010.57% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-1.63 1.33%

Key metrics

Basic
Market capitalization
$6.8b
Enterprise Value
$6.6b
Net debt
positive
Cash
$708.9m
Shares outstanding
56.3m
Valuation (TTM | estimate)
P/E
negative | 70.2
P/S
10.1 | 9.2
EV/Sales
9.8 | 8.9
EV/FCF
62.4
P/B
3.3
Financial Health
Equity Ratio
69.7%
Return on Equity
-1.3%
ROCE
0.9%
ROIC
1.2%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$674.0m | $740.6m
EBITDA
$125.9m | $144.2m
EBIT
$25.1m | $98.9m
Net Income
$-13.8m | $96.7m
Free Cash Flow
$106.0m
Growth (TTM | estimate)
Revenue
-11.4% | 16.7%
EBITDA
98.6% | 46.2%
EBIT
451.2% | 720.4%
Net Income
-462.0% | 479.2%
Free Cash Flow
-11.2%
Margin (TTM | estimate)
Gross
51.0%
EBITDA
18.7% | 19.5%
EBIT
3.7%
Net
-2.1% | 13.1%
Free Cash Flow
15.7%
More
EPS
$-0.3
FCF per Share
$1.9
Short interest
9.3%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

22x Buy
79%
6x Hold
21%

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

Buy
79%
Hold
21%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
674 674
11% 11%
100%
- Direct Costs 330 330
20% 20%
49%
344 344
1% 1%
51%
- Selling and Administrative Expenses 276 276
8% 8%
41%
- Research and Development Expense 47 47
11% 11%
7%
126 126
99% 99%
19%
- Depreciation and Amortization 101 101
43% 43%
15%
EBIT (Operating Income) EBIT 25 25
451% 451%
4%
Net Profit -14 -14
462% 462%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Negative
Seeking Alpha
6 days ago
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...
Neutral
GlobeNewsWire
12 days ago
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.
Positive
Seeking Alpha
20 days ago
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base through a series of acquisitions and new launches, reducing its reliance on any single customer. RGEN stock is down 60% from its highs in the summer of 2021, and Repligen has a pristine balance sheet.
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today